Fact-checked by Grok 2 weeks ago

Relative afferent pupillary defect

Relative afferent pupillary defect (RAPD), also known as Marcus Gunn pupil (named after the Scottish ophthalmologist Robert Marcus Gunn (1850–1909), who first described the phenomenon in 1902), is a clinical sign characterized by an asymmetric to light stimulation between the two eyes, resulting from unilateral or asymmetric damage to the afferent visual pathway, most commonly the or . This defect manifests when light directed into the affected eye produces less pupillary constriction in both eyes compared to stimulation of the unaffected eye, due to impaired transmission of light signals via the . RAPD arises from various underlying etiologies affecting the or , such as , ischemic optic neuropathy, , , and severe . The involves disruption in the retinogeniculate pathway, leading to reduced afferent input that alters the balance between direct and consensual pupillary light reflexes. Diagnosis of RAPD relies primarily on the swinging flashlight test. RAPD is clinically significant as it signals potentially treatable optic neuropathies, enabling early intervention to prevent irreversible vision loss.

Physiology and Pathophysiology

Normal pupillary light reflex

The (PLR) is a fundamental autonomic response that regulates pupil size to optimize retinal illumination and protect the eye from excessive light. In healthy individuals, the afferent limb of the pathway begins in the , where photoreceptors detect light and transmit signals via the (cranial nerve II) through the and optic tract to the pretectal nucleus in the . From there, project bilaterally to the Edinger-Westphal nuclei, which form the parasympathetic component of the oculomotor complex. The efferent limb then travels via the (cranial nerve III) to the , and subsequently through to innervate the sphincter pupillae muscle of the , causing constriction, while the dilator pupillae muscle (innervated sympathetically) opposes this action for dilation in low light. The PLR elicits both direct and consensual responses due to the decussating projections in the . When light stimulates one eye, the ipsilateral pupil constricts directly via the intact pathway to that side's muscle, while the contralateral shows a consensual of equal magnitude, reflecting the bilateral innervation from each pretectal to both Edinger-Westphal nuclei. This symmetry ensures coordinated visual function across both eyes, with normal response times of about one second for initial and about five seconds for redilation to baseline, depending on . Key physiological elements include the contribution of , a in intrinsically photosensitive retinal cells (ipRGCs), which mediates sustained pupillary particularly under prolonged or high-irradiance exposure, complementing the transient responses driven by and photoreceptors. Additionally, the near —triggered by on close objects—involves pupillary (the accommodation- ) via the same efferent pathway but distinct cortical inputs, often overlapping with the PLR to enhance during near tasks; however, the PLR itself remains primarily responsive to changes. In bright , healthy pupils typically constrict briskly to a of 2-4 mm, demonstrating to sustained illumination through a balance of parasympathetic drive and gradual sympathetic modulation, with perfect symmetry between eyes in both direct and consensual responses.

Mechanism of relative afferent pupillary defect

The relative afferent pupillary defect (RAPD), also known as Marcus Gunn pupil, is defined as an asymmetry in the pupillary light reflex where the affected eye demonstrates reduced constriction or paradoxical dilation when light is directed to it, in comparison to the unaffected eye, while the efferent pupillary pathways remain intact. This sign arises from unilateral or asymmetric damage to the afferent visual pathway, typically involving the or severe retinal lesions, which impairs the transmission of light signals to the without affecting the motor output to the pupils. The pathophysiological basis of RAPD stems from a reduction in the afferent input from the damaged eye, leading to weaker overall pupillary constriction when stimulated by light in that eye. In the normal pupillary light reflex, light entering one eye activates retinal ganglion cells, whose axons project via the optic nerve to the pretectal nucleus in the midbrain; from there, signals are relayed bilaterally to the Edinger-Westphal nuclei, resulting in symmetric constriction of both pupils through parasympathetic innervation of the sphincter pupillae muscles. With afferent damage, the pupillomotor signal from the affected eye is diminished, causing both pupils to constrict less vigorously (or dilate relatively) during direct stimulation of the affected eye compared to stimulation of the intact eye. The "relative" aspect emphasizes that RAPD is not an absolute failure of pupillary response but a comparative defect detectable only by alternating light between eyes, as isolated testing of one eye may show some constriction if the lesion is incomplete. Central to this mechanism is the bilateral innervation of the pupillary system, where each eye's stimulus influences both pupils equally under normal conditions; damage to one afferent arm thus creates a detectable imbalance, with greater pupillary observed when light is swung to the affected eye during the swinging . The severity of RAPD is graded clinically from 0.5+ (minimal ) to 4+ (maximal immediate with no ), based on the extent of paradoxical pupillary escape and re-, which correlates with the degree of afferent pathway compromise. This grading provides a qualitative measure of the defect's magnitude without quantifying absolute size changes. RAPD was first described in 1902 by Scottish ophthalmologist Robert Marcus Gunn, who identified it as a clinical sign of dysfunction rather than a distinct entity, highlighting its utility in localizing afferent lesions.

Etiology

Optic nerve disorders

, often associated with , is a common cause of relative afferent pupillary defect (RAPD) due to inflammation and demyelination of the , leading to acute unilateral vision loss and pain on eye movement. In acute unilateral cases, RAPD is detected in approximately 96% of patients, persisting in 92% even after recovery, while in bilateral cases, it appears in about 66% of recovered instances. Ischemic optic neuropathy, encompassing anterior and posterior forms, results from vascular compromise and is prevalent in patients over 50, frequently linked to or cardiovascular risk factors; it presents with sudden, painless visual impairment and swelling in anterior cases. RAPD is a hallmark finding in ischemic optic neuropathy, accompanying decreased , defects, and color vision loss. Compressive lesions, such as those from meningiomas, pituitary adenomas, or tumors, interrupt function through , causing progressive visual deficits and RAPD even with preserved in some instances. optic neuropathy, typically indirect from shear forces in head , damages the canal region and manifests with RAPD alongside severe vision loss, where initial RAPD magnitude exceeding 2.1 log units predicts poor recovery to better than hand motion vision. Glaucomatous in advanced asymmetric stages leads to significant loss, producing RAPD that correlates strongly with circumpapillary thickness asymmetry and defects. RAPD typically emerges in unilateral optic nerve damage involving at least 25% loss of retinal nerve fibers compared to the fellow eye, with greater defects requiring up to 50% fiber reduction in experimental models. Bilateral symmetric optic nerve damage, however, often fails to produce a detectable relative defect due to equal afferent input bilaterally. In optic nerve disorders, RAPD commonly correlates with visual acuity reduction and color vision impairment, serving as an objective indicator of afferent pathway severity beyond subjective visual complaints.

Retinal and other disorders

Relative afferent pupillary defect (RAPD) in disorders typically arises from extensive damage to photoreceptors or vasculature, as the aggregates signals from the entire , requiring significant asymmetry—often affecting more than one-third to half of the surface—for a clinically detectable defect. Unlike isolated lesions, causes are often accompanied by visible fundus abnormalities, such as hemorrhages, , or detachments, identifiable on dilated examination. Severe , particularly macula-off cases involving at least two quadrants (approximately 50% of the ), interrupts afferent signals from large retinal areas, leading to RAPD. (CRAO) causes profound ischemic damage, resulting in a marked RAPD in nearly all cases due to widespread ganglion cell dysfunction. Similarly, ischemic (CRVO) produces RAPD in nearly all affected eyes (over 90% with significant defects), correlating with the extent of capillary non-perfusion and retinal whitening. Advanced or age-related with extensive photoreceptor loss (>50% retinal involvement) can elicit a mild to moderate RAPD in unilateral or asymmetric presentations, though bilateral symmetry often masks it. Other retinal conditions, such as severe intraocular tumors (e.g., choroidal melanoma) or extensive infectious retinitis (e.g., cytomegalovirus or herpes simplex), may induce RAPD when they compromise substantial retinal tissue. Recent reports highlight increasing recognition of RAPD in post-COVID-19 retinal vascular events, including CRAO-like occlusions with anterior segment and asymmetric ischemia. Beyond direct retinal pathology, non-optic nerve causes of RAPD are less common and usually mild. Severe (visual acuity ≤20/400) can produce a subtle RAPD due to longstanding cortical and retinal adaptation imbalances, though it is rare and requires profound acuity loss. Dense unilateral cataracts can produce an apparent relative afferent pupillary defect in the contralateral eye by altering pupillomotor effectiveness, with studies quantifying defects up to 0.6 log units in asymmetric cases; this underscores the need to evaluate for posterior segment pathology. occasionally presents with paradoxical pupillary responses linked to dysfunction and . Bilateral asymmetric damage, such as from prior ocular surgery in one eye, can also yield RAPD if it results in uneven retinal or pre-chiasmal input. These atypical causes underscore the need for comprehensive anterior and posterior segment evaluation to distinguish them from more common etiologies.

Clinical Presentation

Pupillary signs

The primary pupillary sign of relative afferent pupillary defect (RAPD) is observed during the swinging flashlight test, where light swung from the unaffected eye to the affected eye causes paradoxical dilation of both pupils, with the affected pupil showing greater dilation due to reduced afferent input from the or . In contrast, static light testing reveals normal direct and consensual pupillary responses, with both pupils constricting equally and briskly to light directed at either eye, as the defect only manifests under comparative dynamic conditions. Grading of RAPD is typically subjective, using a scale from grade 1+ (minimal initial constriction followed by slight redilation in the affected eye) to 5+ (immediate dilation with no secondary constriction after prolonged illumination of the good eye), allowing clinicians to assess severity based on the degree of dilation observed. Objective quantification measures pupil size changes in millimeters or uses neutral density filters to determine the defect in log units, with a minimum detectable RAPD often around 0.3 log units corresponding to subtle dilation of approximately 0.5 mm. Associated pupillary features may include mild ( size asymmetry greater than 1 mm), particularly in longstanding cases, though this is not intrinsic to RAPD and can complicate detection by inducing a small apparent defect in the smaller pupil (about 0.1 log units per 1 mm difference). Unlike efferent pupillary defects, such as those in third nerve palsy, RAPD spares the efferent pathway, resulting in no inherent or fixed dilation and preserving symmetric consensual responses. As a relative sign, RAPD requires asymmetric afferent function between eyes and is maximally evident in complete unilateral blindness if the contralateral eye has normal vision, where swinging the light to the affected eye causes both pupils to dilate fully due to the complete absence of comparative afferent input; it is also evident with unilateral severe damage when some residual afferent input remains in the affected eye.

Associated visual symptoms

Patients with relative afferent pupillary defect (RAPD) due to involvement commonly report ; visual field defects vary by etiology, such as central in or altitudinal defects respecting the horizontal meridian in ischemic optic neuropathies like nonarteritic (NAION). In causes of RAPD, symptoms typically include loss and , characterized by distorted or wavy images, particularly when the is affected. These visual complaints are usually unilateral, highlighting the asymmetry of afferent input damage, and may present acutely or gradually depending on the underlying process. Patient history often reveals an acute onset in cases like , where vision loss develops over hours to days and may include pain with eye movement, contrasting with more gradual progression in conditions such as . The unilateral nature of these symptoms underscores the relative asymmetry, with RAPD emerging as an early indicator before profound vision loss in over 90% of acute unilateral optic neuritis cases. Objective findings include reduced ranging from light perception to 20/20, though RAPD nearly always correlates with some degree of . Color desaturation, particularly desaturation, is a frequent accompaniment in optic neuropathies, detectable via targeted testing. testing further reveals defects corresponding to the lesion site, such as central or cecocentral scotomas in involvement or peripheral constriction in disorders.

Diagnosis

Swinging flashlight test

The swinging flashlight test, also known as the Marcus Gunn pupil test, serves as the primary bedside method for detecting a relative afferent pupillary defect (RAPD) by assessing in the . This test exploits the difference in afferent input from each eye, revealing or severe retinal dysfunction when one eye's stimulus fails to sustain constriction. The procedure is conducted in a dimly lit to enhance pupil and test sensitivity. The patient fixates on a distant target, such as a , to prevent accommodative that could confound results. A bright, focused , typically a penlight or halogen with a narrow beam, is directed perpendicularly into one eye from approximately 40-50 cm away for 2-3 seconds, eliciting direct constriction in the illuminated pupil and consensual constriction in the fellow pupil. The is then swiftly swung to the other eye—taking less than 1 second to minimize —and held for another 2-3 seconds while both pupils are closely observed, often using or a for precision. The process is repeated several times, alternating eyes, to confirm findings. Interpretation relies on comparing pupil responses during the swing. In normal eyes, both pupils maintain equal or further constrict symmetrically, reflecting balanced afferent signals. A positive RAPD is present if the affected pupil dilates paradoxically when light swings from the unaffected eye to it, due to weaker afferent drive failing to inhibit the midbrain's pupilloconstrictor output; this indicates the tested eye has the defect. Grading is subjective: trace/subtle (slight initial before dilation), 1+ to 2+ (delayed dilation), or 3+ to 4+ (immediate marked dilation), with amaurotic denoting no perception in the affected eye. The pupillary sign was first described by Marcus Gunn in the early 1900s, and the test is highly sensitive for unilateral lesions such as . Technique variations address subtle or equivocal cases. Neutral density filters (e.g., 0.3 log units initially) placed over the unaffected eye during swinging can quantify the RAPD by titrating the filter density until the paradoxical dilation is neutralized, providing an objective measure in log units. Care must be taken to maintain consistent light intensity and distance between eyes to avoid artifacts from unequal illumination.

Advanced diagnostic methods

Advanced diagnostic methods for relative afferent pupillary defect (RAPD) extend beyond subjective clinical maneuvers by providing objective quantification of pupillary responses and aiding in localization through electrophysiological and techniques. These methods are particularly valuable in cases where the swinging flashlight test yields equivocal results, such as bilateral optic neuropathies, or when precise measurement of RAPD severity is required for monitoring disease progression. Pupillometry employs infrared video or digital pupillometers to objectively measure parameters including , , and in response to stimuli, allowing for quantification of RAPD as the percentage difference in pupillary between eyes. For instance, an asymmetry exceeding 0.6 log units or approximately 20% difference in is often indicative of a clinically significant RAPD. Automated handheld devices, such as the RAPiDo pupillometer, have demonstrated high reliability in detecting and grading RAPD in asymmetric , correlating pupillary asymmetry with defects and thinning. Recent advancements include virtual reality-based pupillometers, which achieve diagnostic accuracy comparable to systems for unilateral neuro-ophthalmic pathologies. A 2025 study highlighted pupillometry's utility in assessing age-related pupil changes, noting reduced amplitudes in older adults that can mimic or mask RAPD, emphasizing its role in equivocal bilateral cases. Electrophysiological tests complement pupillometry by evaluating neural conduction along the afferent pathway. Visual evoked potentials (VEP) detect delays or amplitude reductions in signaling, confirming RAPD associated with conduction defects in or compressive lesions, with studies showing significant correlations between VEP abnormalities and RAPD severity. Multifocal electroretinography (mfERG) assesses localized retinal function, proving useful for RAPD due to macular or widespread retinal disorders like age-related macular degeneration, where it reveals topographic response asymmetries not evident in full-field ERG. Imaging modalities provide structural correlations to RAPD findings, aiding in etiology determination. (OCT) measures thickness, with studies demonstrating a strong inverse relationship between RNFL thinning and RAPD magnitude in glaucomatous and non-glaucomatous optic neuropathies; for example, inter-eye RNFL differences greater than 10 μm often align with detectable RAPD. (MRI) visualizes , chiasmal, or retrochiasmal lesions underlying RAPD, such as in demyelinating diseases, where T2-weighted sequences reveal enhancement or atrophy correlating with pupillary asymmetry. These techniques collectively enable precise diagnosis and differentiation of pre-chiasmal from post-chiasmal causes.

Management and Prognosis

Treatment of underlying causes

The treatment of relative afferent pupillary defect (RAPD) focuses on addressing the underlying , as RAPD itself is a sign of afferent pathway dysfunction rather than a primary condition requiring direct intervention. Prompt identification and management of the causative disorder are essential to preserve visual function and potentially allow for recovery of the as afferent pathways heal. For optic nerve disorders, high-dose intravenous corticosteroids, such as 1 g of daily for 3 days followed by an oral taper, are the standard initial therapy for to accelerate visual recovery and reduce inflammation. In cases of nonarteritic anterior ischemic optic neuropathy, intravitreal anti-vascular endothelial growth factor () agents like may be administered to reduce optic disc and capillary permeability, though evidence remains limited to observational studies showing potential short-term benefits. For compressive optic neuropathies due to tumors or bony lesions, surgical decompression of the via endoscopic or transcranial approaches can relieve pressure on the nerve, stabilizing or improving vision in select cases. Retinal interventions target specific pathologies contributing to RAPD. Vitrectomy surgery is commonly performed for rhegmatogenous , involving removal of the vitreous gel and relief of traction to reattach the and restore afferent input. In acute central , intravenous with within 4.5 hours has not shown significant benefit over conservative management like aspirin, based on the 2025 trial (a multicentre, randomised, double-blind study showing no difference in visual improvement, 66% vs. 48%, p=0.95). Other approaches, such as ocular , anterior chamber , or , may be considered, though evidence remains limited; antiplatelet agents like aspirin are used for to prevent recurrence and support vascular patency. For glaucoma-related RAPD, neuroprotective agents such as brimonidine or are under investigation in experimental trials, aiming to protect beyond reduction, with preliminary studies suggesting modest preservation of visual fields. Emerging therapies for hereditary optic neuropathies, a subset of causes, include intravitreal with vectors like lenadogene nolparvovec for Leber hereditary , which has shown sustained bilateral improvements up to five years post-treatment in clinical trials completed by 2025. A multidisciplinary approach involving neurologists and ophthalmologists is crucial for comprehensive evaluation and coordinated care, ensuring etiology-specific interventions are optimized.

Clinical outcomes and monitoring

The prognosis of relative afferent pupillary defect (RAPD) varies significantly depending on the underlying etiology. In cases associated with , particularly in , approximately 95% of patients achieve of 20/40 or better, often within 2-3 months of onset, though RAPD may persist even after visual recovery. In contrast, advanced typically results in permanent visual field defects and persistent RAPD, as it reflects irreversible damage, with RAPD present in about 23% of primary open-angle glaucoma cases indicating progression. Retinal detachment involving the often leads to poorer postoperative visual outcomes when RAPD is evident, with lasting afferent defects due to photoreceptor loss. Traumatic causes, such as contusion, yield variable recovery, influenced by injury severity, with some patients regaining function through while others experience chronic impairment. Ongoing monitoring is essential to detect progression or complications in RAPD, typically involving serial automated visual field perimetry to track scotomas, optical coherence tomography (OCT) to measure retinal nerve fiber layer thinning, and repeat pupillometry or swinging flashlight testing every 3-6 months to quantify RAPD severity. These strategies help identify bilateral involvement or worsening asymmetry early, guiding adjustments in management for underlying conditions like demyelinating diseases. Complications of RAPD include recurrent episodes in demyelinating disorders, with recurrence rates up to 35% in multiple sclerosis-related , leading to cumulative damage and potential vision deterioration. Untreated vascular causes, such as ischemic , carry a high of legal blindness due to progression. According to StatPearls data from 2023, RAPD resolution often lags behind visual recovery by several weeks in recoverable etiologies like . Recent 2025 analyses emphasize improved visual outcomes in compressive with early MRI-guided surgical interventions, achieving better preservation of afferent function when occurs within weeks of symptom onset.

References

  1. [1]
    Relative Afferent Pupillary Defect - EyeWiki
    Mar 17, 2025 · Relative afferent pupillary defect (RAPD) is a condition in which pupils respond differently to light stimuli shone in one eye at a time.
  2. [2]
    Marcus Gunn Pupil - Cleveland Clinic
    The condition is named after Robert Marcus Gunn, an ophthalmologist in the late 1800s. It might also be called relative afferent pupillary defect (RAPD), Gunn's ...Missing: reliable sources
  3. [3]
    How to test for a relative afferent pupillary defect (RAPD) - PMC
    A positive RAPD means there are differences between the two eyes in the afferent pathway due to retinal or optic nerve disease. If the light used is ...Missing: reliable | Show results with:reliable
  4. [4]
    Pupillary Responses | Stanford Medicine 25
    Relative Afferent Pupillary Defect (RAPD, Marcus Gunn Pupil). An RAPD is a defect in the direct response. It is due to damage inoptic nerve or severe retinal ...Missing: reliable | Show results with:reliable
  5. [5]
    Neuroanatomy, Pupillary Light Reflexes and Pathway - NCBI - NIH
    Sep 15, 2025 · Anatomical Components of the Visual and Pupillary Light Reflex Pathways · Cornea · Iris and Pupil · Lens · Retina · Optic Nerve, Chiasm, and Tracts.Introduction · Structure and Function · Nerves · Muscles
  6. [6]
    Pupillary Light Reflex - StatPearls - NCBI Bookshelf - NIH
    The pupillary light reflex constricts the pupil in response to light, and pupillary constriction is achieved through the innervation of the iris sphincter ...Continuing Education Activity · Anatomy and Physiology · Clinical Significance
  7. [7]
    Ocular Motor System (Section 3, Chapter 7) Neuroscience Online
    Interactive Illustration. The pupillary light reflex pathway involves the optic nerve and the oculomotor nerve and nuclei. Parasympathetic Innervation of the ...
  8. [8]
    Melanopsin and Rod–Cone Photoreceptors Play Different Roles in ...
    Oct 10, 2012 · In mammals, the pupillary light reflex is mediated by intrinsically photosensitive melanopsin-containing retinal ganglion cells that also ...
  9. [9]
    Normal pupillary size in fluorescent and bright light - PubMed
    The mean pupillary size in fluorescent light was 3.6+/-0.7 mm, and the mean size in bright light was 2.6+/-0.5 mm. Extreme values in fluorescent light were ...
  10. [10]
    Relative Afferent Pupillary Defect - EyeWiki
    Mar 17, 2025 · Relative afferent pupillary defect (RAPD) is a condition in which pupils respond differently to light stimuli shone in one eye at a time.Background · Retinal Causes of a Relative... · Other Causes of a Relative...
  11. [11]
    Marcus Gunn Pupil - StatPearls - NCBI Bookshelf
    Aug 25, 2023 · A relative afferent pupillary defect usually indicates disease in the pre chiasmal visual pathway.[3] The ability to detect and quantify ...Etiology · Pathophysiology · Evaluation · Differential Diagnosis
  12. [12]
    Relative Afferent Pupillary Defect (RAPD) - Moran CORE
    Relative Afferent Pupillary Defect (RAPD) · If that eye is normal, both pupils will constrict slightly · If RAPD is present in that eye, both pupils will dilate.Missing: reliable | Show results with:reliable
  13. [13]
    Clinical grading of relative afferent pupillary defects - PubMed
    The grading system can be compared with the neutral density filter grading system, and each grade has a corresponding value in log units.
  14. [14]
    Robert Marcus Gunn - LITFL
    Jun 13, 2025 · 1902 First description by Robert Marcus Gunn · Gunn's pupil / Gunn's phenomenon – Relative afferent pupillary defect observed with alternating ...
  15. [15]
    Relative afferent pupillary defects in optic neuritis - PubMed - NIH
    One can find relative afferent pupillary defects in nearly all patients with unilateral optic neuritis and in most patients with bilateral disease.Missing: nerve causing
  16. [16]
    Ischemic optic neuropathy - PubMed
    Examination findings usually include decreased visual acuity, a visual field defect, color vision loss, a relative afferent pupillary defect, and a swollen ...
  17. [17]
    Relative afferent pupillary defect with normal vision and ... - PubMed
    Conclusions: A pathologic RAPD with normal vision can be caused by tumour compression of the contralateral pretectal nucleus or its afferent or efferent fibres.
  18. [18]
    Predictive value of the initial quantified relative afferent pupillary ...
    Methods: The RAPD was measured and quantified by neutral density filters in patients with unilateral indirect traumatic neuropathy. All patients were treated ...
  19. [19]
    Detection of Relative Afferent Pupillary Defect and Its Correlation ...
    Jun 8, 2023 · Patients with asymmetric glaucomatous optic neuropathy (GON) present a relative afferent pupillary defect (RAPD) in the eye with more advanced ...
  20. [20]
    Quantification of retinal nerve fiber layer thickness reduction ...
    Conclusions: RAPD was not clinically detected until at least approximately 25% of the retinal nerve fibers were lost when compared with the unaffected eyes.Missing: loss | Show results with:loss
  21. [21]
    Optic Neuropathies - PubMed
    Apr 1, 2025 · Signs of optic nerve dysfunction include decreased visual acuity, color vision impairment, a relative afferent pupillary defect in the affected ...
  22. [22]
    Diagnosis and Management of Central Retinal Artery Occlusion
    Aug 1, 2017 · On examination, a relative afferent pupillary defect occurs regardless of the visual acuity or macular sparing. Classic ophthalmoscopic ...
  23. [23]
    Relative afferent pupillary defect in central retinal vein occlusion
    In a prospective study, 120 patients with unilateral central retinal vein occlusion (CRVO) were investigated to determine the role of the relative afferent ...Missing: causes | Show results with:causes
  24. [24]
    Post COVID-19 Ophthalmic Manifestations in an Asian Indian Male
    May 19, 2021 · He had bilateral anterior chamber inflammation with a relative afferent pupillary defect in the RE. RE showed central retinal artery ...
  25. [25]
    A unilateral cataract produces a relative afferent pupillary defect in ...
    The relative afferent pupillary defect (RAPD) was measured with neutral density filters in ten patients, each of whom had a dense cataract in one eye only.
  26. [26]
    Relative afferent pupillary defect in patients with asymmetric cataracts
    Relative afferent pupillary defect in patients with asymmetric cataracts. J Cataract Refract Surg. 2004 Jan;30(1):132-6. doi: 10.1016/j.jcrs.2003.11.022 ...
  27. [27]
    Infantile Nystagmus - American Academy of Ophthalmology
    Sep 27, 2017 · Detection of a relative afferent pupillary defect provides ... Paradoxical pupillary responses in congenital stationary night blindness.
  28. [28]
    Nonarteritic Anterior Ischemic Optic Neuropathy - StatPearls - NCBI
    Visual loss may be noticed as a dark spot in the superior or inferior field, consistent with an altitudinal defect. The degree of visual impairment varies, ...
  29. [29]
    Acute-Onset Retinal Conditions Mimicking Acute Optic Neuritis
    Sep 1, 2023 · Metamorphopsia: distortion of images is a clear indicator of a maculopathy as the cause of visual loss. Straight lines appear wavy and may be ...
  30. [30]
    Demyelinating Optic Neuritis - EyeWiki
    Jun 2, 2025 · Signs. Decreased visual acuity; Decreased color vision (red desaturation) and/or decreased contrast/brightness sense ... optic neuropathy ...
  31. [31]
    Correlation between relative afferent pupillary defect and visual field ...
    May 26, 2022 · The RAPD clinical plus scale was divided into grade 1+, initial weak constriction; grade 2+, initial stall then dilatation; grade 3+, immediate ...
  32. [32]
    Detection of Relative Afferent Pupillary Defect and Its Correlation ...
    This study assessed RAPD in 81 patients with GON using Hitomiru, a novel hand-held infrared binocular pupillometer.
  33. [33]
    Quantification of RAPD by an automated pupillometer in asymmetric ...
    The purpose of this study was to quantify RAPD by a pupillometer (RAPiDo, Neuroptics) and assess its correlation with asymmetric glaucoma and manual pupillary ...Abstract · Figure 2 · Discussion
  34. [34]
    Examining pupil characteristics and relative afferent pupil defect ...
    May 12, 2025 · Causes of relative afferent pupillary defect (RAPD). Comparing the mean age of individuals with a relative afferent pupillary defect (RAPD) to ...
  35. [35]
    Predictive value of visual evoked potentials, relative afferent ... - NIH
    The purpose of this study was to determine the predictive value of flash visual-evoked potentials (VEP), relative afferent pupillary defect, and presence of ...
  36. [36]
    Analysis of retinal nerve fibre layer, visual evoked potentials and ...
    The aim of this study was to analyse retinal nerve fibre layer (RNFL), pattern-reversal visual evoked potentials (pVEPs) and relative afferent pupillary defect ...
  37. [37]
    Multifocal electroretinogram contributes to differentiation of ... - Nature
    Jul 4, 2014 · In the early 1990s, the multifocal electroretinogram (mfERG) was developed as a means by which to record topographic retinal activity. The ...Missing: RAPD | Show results with:RAPD
  38. [38]
    Correlation of Relative Afferent Pupillary Defect and Retinal Nerve ...
    They concluded that a 0.6-log unit RAPD developed after unilateral RNFL loss of 25% to 50% and postulated that this threshold effect might have been caused by ...
  39. [39]
  40. [40]
    Marcus Gunn Pupil: What Is It, Causes, Treatment, and More | Osmosis
    Marcus Gunn pupil refers to the unequal pupillary response to light due to damage or disease in the retina or optic nerve.Missing: procedure interpretation
  41. [41]
    The Effect of Corticosteroids for Acute Optic Neuritis on the ...
    Dec 9, 1993 · Treatment with a three-day course of high-dose intravenous methylprednisolone (followed by a short course of prednisone) reduces the rate of development of ...
  42. [42]
    Intravitreal Aflibercept for Patients with Acute Nonarteritic Anterior ...
    Jul 24, 2023 · The administration of anti-VEGF agents leads to a decrease in capillary permeability, resulting in accelerated resolution of optic disc edema.2. Methods · 2.1. Data Collection · 3. Results
  43. [43]
    Optic Nerve Decompression | University of Miami Health System
    Endoscopic optic nerve decompression is a minimally invasive procedure used to relieve some of the pressure on the optic nerve and stabilize or improve vision.
  44. [44]
    What Is Vitrectomy? - American Academy of Ophthalmology
    Oct 1, 2024 · Vitrectomy is eye surgery used to treat problems of the eye's retina and vitreous. An ophthalmologist may remove blood from inside the eye, ...
  45. [45]
    Thrombolytic Therapy for Acute Central Retinal Artery Occlusion
    Dec 23, 2019 · Intravenous thrombolysis reduces morbidity from acute ischemic stroke when given within 4.5 hours of the time a person was last free of symptoms ...
  46. [46]
    Antithrombotic treatment of retinal vein occlusion - PubMed Central
    The use of antiplatelet therapy in RVO is supported by the results of only one placebo-controlled trial. This study compared six months of therapy with ...
  47. [47]
    Neuroprotection in Glaucoma - EyeWiki
    Nov 1, 2025 · Neuroprotection in glaucoma refers to non-IOP-related interventions that can prevent or delay glaucomatous neurodegeneration, ...Brimonidine · Stem Cell Therapy · Neurotrophins · Ocular Blood Flow Regulating...
  48. [48]
    GenSight's Optic Neuropathy gene therapy sustains efficacy over ...
    Feb 12, 2025 · GenSight's gene therapy treatment for patients living with Leber hereditary optic neuropathy (LHON) has demonstrated sustained efficacy and eyesight ...
  49. [49]
    A Prospective Study Of Ocular Manifestations In Head Injury Patients ...
    Patients were managed by a multidisciplinary approach. ... The most frequently encountered neuro-ophthalmological manifestation was pupillary involvement as RAPD ...
  50. [50]
    20/40 or Better Visual Acuity After Optic Neuritis - PubMed
    Background: Although patients with acute optic neuritis (ON) recover high-contrast visual acuity (HCVA) to 20/40 or better in 95% of affected eyes, patients ...Missing: rate | Show results with:rate
  51. [51]
    Optic Neuritis - StatPearls - NCBI Bookshelf - NIH
    Jan 20, 2025 · Color vision testing: Particular attention should be given to red desaturation. Pupillary examination: The presence of RAPD should be determined ...
  52. [52]
    Visual outcomes in patients with meningiomas compressing optic ...
    Jun 12, 2025 · This study retrospectively evaluates the impact of surgical intervention on visual recovery in patients with optic nerve–compressing meningiomas.Missing: RAPD | Show results with:RAPD